Investigation on Soleno Therapeutics and Its Shareholders
The legal representatives at Johnson Fistel, PLLP are currently probing potential issues involving Soleno Therapeutics, Inc. (NASDAQ: SLNO). They aim to determine if the company and its executives breached federal securities regulations by possibly issuing misleading statements or neglecting to share essential information with investors.
This inquiry particularly revolves around Soleno's public statements about the commercialization of its product, VYKAT™ XR, after it received FDA approval. The firm seeks to understand if these communications accurately conveyed the drug's market performance and safety.
Concerns Raised About VYKAT™ XR
Upon its introduction to the market in September, Soleno indicated that VYKAT™ XR was achieving impressive results beyond its internal forecasts. However, during a call regarding its third-quarter earnings, the company recognized several complications following the product launch.
Management noted a decline in new treatments and an increase in discontinuations of therapy due to minor adverse effects. They acknowledged the impact of outside criticism that emerged earlier, which had a significant influence on the market's perception of the product.
Critical Report by Short Seller
In August 2025, a report from short seller Scorpion Capital raised alarms about VYKAT™ XR and its market strategies. It cast doubt on the drug's safety profile, questioned the sustainability of its demand, and highlighted risks associated with the concentration of initial prescriptions.
Scorpion Capital also criticized the business model of Soleno, pointing out its heavy reliance on a single product whose intellectual property is expected to face challenges imminently. This negative sentiment was compounded by the recommendation for further scrutiny of certain clinical studies related to VYKAT™ XR.
Stock Price Fluctuations
Following the unsettling report on August 15, 2025, there was marked volatility in Soleno's stock market performance. The company's share value plummeted nearly 40% from August 14 to November 5, 2025, reflecting investor concerns and the market's reaction to the critical feedback.
Investors who purchased shares and are facing losses should consider joining the investigation led by Johnson Fistel. The firm emphasizes that there is no financial obligation for participants, making it a beneficial opportunity for those affected.
About Johnson Fistel, PLLP
Johnson Fistel, PLLP, is well-regarded across the nation as a leading shareholder rights law firm with various offices throughout multiple states. The firm is devoted to representing both individual and institutional investors, particularly in cases concerning securities class actions and shareholder derivative lawsuits.
Notably, the firm has extended its reach to overseas investors who acquired shares on U.S. exchanges, providing comprehensive support for their rights and interests.
Recognitions and Achievements
In recent years, Johnson Fistel has attained significant accolades, ranking within the top 10 plaintiff law firms by ISS Securities Class Action Services in 2024. This recognition stems from their successful recovery of approximately $90.7 million for investors across various cases where they took on lead or co-lead roles.
As the firm continues to excel, their commitment to protecting investor rights remains steadfast, enhancing trust among clients and stakeholders alike.
Frequently Asked Questions
What is the current status of the investigation into Soleno Therapeutics?
The investigation by Johnson Fistel is ongoing, focusing on potential violations of securities laws by Soleno and its executives.
What were the key issues raised regarding VYKAT™ XR?
Concerns included the drug's safety profile, demand sustainability, and the subsequent drop in therapy initiations and increased discontinuations.
How did the Scorpion Capital report affect Soleno's stock?
Following the report, Soleno's stock experienced significant declines, losing nearly 40% of its value within a few months.
Who should join the investigation?
Any investors who purchased SLNO securities and incurred losses are encouraged to participate in the investigation.
What does Johnson Fistel offer to affected shareholders?
The firm provides their services at no cost, aiming to help shareholders understand their rights and the potential for recovery.
